AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Autolus Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.59−0.01 (-0.63%)
Close on Oct 19, 2026
- Market cap
- $423.19M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.03 (−1.85%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Autolus Therapeutics plc grew revenue 292.2% to $117.39M over the twelve months to Jun 30, 2026. Free cash flow was -$232.73M.
Revenue
$117.39M
+292.2% vs. a year earlier
Operating income
-$247.44M
TTM Q2 2026
Free cash flow
-$232.73M
TTM Q2 2026
EPS, diluted
-$1.06
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $423.19M
- P/E ratio
- –
- Price to sales
- 3.61
- Price to book
- 5.65
- Dividend yield
- –
- Free cash flow yield
- -54.99%
Fundamentals
- Revenue
- $117.39M
- Net income
- -$280.16M
- EPS, diluted
- -$1.06
- Free cash flow
- -$232.73M
- Book value per share
- $0.28
- Diluted shares
- 266M
Ten years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$117.39M+292.2% YoY
Gross profit
$18.38M
Operating income
-$247.44M
Net income
-$280.16M
EPS, diluted
-$1.06
Free cash flow
-$232.73M
Reported periodTrailing twelve months